Lipid nanocarrier，LNC
FRx LNC
FRx LNC
The development of FRx LNC was driven by the observation that many drug delivery carriers, in addition to having complex processes that are not conducive to clinical production, have poor drug encapsulation efficiency, resulting in excessive use of excipients that can cause inappropriate side effects and toxicity. These factors have limited the development of these nano-carriers. For this reason, FormuRx has developed a new drug delivery system, FRx LNC, with the goal of improving drug encapsulation.
Applicable dosage form and product application types
Applicable dosage form: Injection
Product application types
- Small molecule drugs
FRx LNC-compatible drug properties/ ImprovePoints
- Electrically charged small molecule drugs/
Low encapsulated efficiency
Advantages
- Overcoming the limitation of traditional lipid-based nanocarriers
- Using microfluidic technology to solve the scaling-up challenges of traditional formulations
- FormuRx's Post-modification technology can enhance the stability of FRx LNC in serum or during preservation
Technical implementation example
High encapsulated efficiency
Uniform size
Stability enhancement
- Increase the encapsulated efficiency by 2-10 times
- Uniform size and stable qualility
- Maintains over 80% stability in serum or during preservation
Patent and Publication
- US-2022-0296514-A1.
- US-2022-0296518-A1.
- Biomedicines 2022, 10, 1259.
Partnership
FormuRx's core team is well-versed in the key physicochemical properties and delivery technologies of formulation development in the commercialization process. With a focus on lipid-based drug delivery system as a unique delivery technology, we offer collaborative development or services for the benefit of patients and the industry.
Phone
+886-2-2367-6828
service@formurx.com
Location
Rm. B406, No. 18, Siyuan St., Zhongzheng Dist., Taipei City 100,Taiwan (R.O.C.)